SG11201706281YA - Use of plinabulin in combination with immune checkpoint inhibitors - Google Patents

Use of plinabulin in combination with immune checkpoint inhibitors

Info

Publication number: SG11201706281YA
Authority: SG; Singapore
Prior art keywords: plinabulin; combination; immune checkpoint; checkpoint inhibitors; inhibitors
Prior art date: 2015-02-12

Application number

SG11201706281YA

Inventor

Lan Huang

Gloria Tsi-Yie Lee

Original Assignee

Beyondspring Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-12

Filing date

2016-02-11

Publication date

2017-09-28

2016-02-11 Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc

2017-09-28 Publication of SG11201706281YA publication Critical patent/SG11201706281YA/en

Links

229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title 1
229950011498 plinabulin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG11201706281YA 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors SG11201706281YA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562115468P	2015-02-12	2015-02-12
US201562255259P	2015-11-13	2015-11-13
PCT/US2016/017602 WO2016130839A1 (en)	2015-02-12	2016-02-11	Use of plinabulin in combination with immune checkpoint inhibitors

Publications (1)

Publication Number	Publication Date
SG11201706281YA true SG11201706281YA (en)	2017-09-28

Family

ID=56615698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201706281YA SG11201706281YA (en)	2015-02-12	2016-02-11	Use of plinabulin in combination with immune checkpoint inhibitors

Country Status (17)

Country	Link
US (1)	US20180028531A1 (en)
EP (1)	EP3256130A4 (en)
JP (3)	JP7243021B2 (en)
KR (1)	KR20170117113A (en)
CN (2)	CN107427510A (en)
AU (3)	AU2016219204B2 (en)
BR (1)	BR112017016902A2 (en)
CA (1)	CA2975729A1 (en)
CL (1)	CL2017002050A1 (en)
HK (1)	HK1247816A1 (en)
IL (2)	IL286282B2 (en)
MX (2)	MX2017010338A (en)
MY (1)	MY193968A (en)
NZ (1)	NZ734256A (en)
RU (1)	RU2723021C2 (en)
SG (1)	SG11201706281YA (en)
WO (1)	WO2016130839A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10441654B2 (en)	2014-01-24	2019-10-15	Children's Hospital Of Eastern Ontario Research Institute Inc.	SMC combination therapy for the treatment of cancer
KR102626155B1 (en)	2015-03-06	2024-01-17	비욘드스프링 파마수티컬스, 인코포레이티드.	RAS omitted
MX2017011375A (en)	2015-03-06	2018-01-23	Beyondspring Pharmaceuticals Inc	Method of treating a brain tumor.
WO2016197204A1 (en) *	2015-06-11	2016-12-15	Bionomics Limited	Pharmaceutical combination and uses thereof
EP4011878A1 (en)	2015-07-13	2022-06-15	Beyondspring Pharmaceuticals, Inc.	Plinabulin compositions
CA3013467A1 (en)	2016-02-08	2017-08-17	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
TWI808055B (en)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Combination therapies of hdac inhibitors and pd-l1 inhibitors
KR20230018545A (en)	2016-06-06	2023-02-07	비욘드스프링 파마수티컬스, 인코포레이티드.	Composition and method for reducing neutropenia
EP3505183B1 (en) *	2016-08-26	2022-03-30	Tetsuji Okuno	Microvascular blood flow decreasing agent and use thereof
SG11201902974PA (en) *	2016-10-14	2019-05-30	Merck Sharp & Dohme	Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP2020503363A (en)	2017-01-06	2020-01-30	ビヨンドスプリングファーマシューティカルズ，インコーポレイテッド	Tubulin binding compounds and their therapeutic use
KR20190109479A (en)	2017-02-01	2019-09-25	비욘드스프링 파마수티컬스, 인코포레이티드.	How to reduce neutropenia
CN110603037A (en) *	2017-03-13	2019-12-20	大连万春布林医药有限公司	Plinabulin compositions and uses thereof
EP3658143A4 (en) *	2017-07-26	2021-04-21	Chong Kun Dang Pharmaceutical Corp.	Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
CA3074876A1 (en) *	2017-09-08	2019-03-14	University Health Network	Combination therapies for inhibition of polo-like kinase 4
CN109498627B (en) *	2017-09-15	2021-06-04	深圳华大海洋科技有限公司	Pharmaceutical composition for treating tumors and application thereof
JP7350015B2 (en) *	2018-01-24	2023-09-25	ビヨンドスプリングファーマシューティカルズ，インコーポレイテッド	Compositions and methods for reducing thrombocytopenia due to administration of plinabulin
CA3101612A1 (en) *	2018-06-01	2019-12-05	Beyondspring Pharmaceuticals, Inc.	Composition and method of treating cancer associated with egfr mutation
CN108524442B (en) *	2018-06-05	2022-01-28	深圳海王医药科技研究院有限公司	Injection of antineoplastic medicine and its preparing process
MX2021001762A (en) *	2018-08-16	2021-04-19	Beyondspring Pharmaceuticals Inc	Method and composition for stimulating immune response.
JP2022506464A (en) *	2018-11-01	2022-01-17	ノースカロライナステートユニバーシティ	Delivery of anticancer drugs via fat cells
CN110265095A (en) *	2019-05-22	2019-09-20	首都医科大学附属北京佑安医院	For HCC recurrence and construction method and the application of the prediction model and nomogram of RFS
CN112778155B (en) *	2019-11-11	2023-08-11	大连万春布林医药有限公司	Tucarbaryl derivatives and uses thereof
US20230181605A1 (en) *	2020-05-04	2023-06-15	Beyondspring Pharmaceuticals, Inc.	Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
WO2022133492A1 (en) *	2020-12-18	2022-06-23	Beyondspring Pharmaceuticals, Inc.	Compositions and methods for generating anti-tumor immune response
EP4319751A1 (en) *	2021-04-09	2024-02-14	Beyondspring Pharmaceuticals, Inc.	Therapeutic compositions and methods for treating tumors
CN113456643B (en) *	2021-08-11	2022-04-01	遵义医科大学	Pharmaceutical composition containing plinabulin and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100540548C (en)	2002-08-02	2009-09-16	尼瑞斯药品公司	Synthesizing of dehydrophenylahistin and analogue thereof and dehydrophenylahistin and analogue thereof
NZ548659A (en) *	2004-02-04	2011-01-28	Nereus Pharmaceuticals Inc	Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DK2439273T3 (en) *	2005-05-09	2019-06-03	Ono Pharmaceutical Co	HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH-1 (PD-1) AND PROCEDURES FOR TREATMENT OF CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNTER APPLICATIONS
US8569262B2 (en) *	2007-11-02	2013-10-29	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2558568T3 (en) *	2008-01-08	2016-02-05	Bristol-Myers Squibb Company	Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
MX366955B (en)	2009-09-15	2019-07-31	Bluelink Pharmaceuticals Inc	Treatment of cancer.
US20130064831A1 (en) *	2010-05-17	2013-03-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) *	2010-09-15	2012-03-22	Tokyo University Of Pharmacy And Life Sciences	Plinabulin prodrug analogs and therapeutic uses thereof
WO2013090552A1 (en) *	2011-12-13	2013-06-20	Yale University	Compositions and methods for reducing ctl exhaustion
EP2911669B1 (en) *	2012-10-26	2024-04-10	The University of Chicago	Synergistic combination of immunologic inhibitors for the treatment of cancer
CN105358576B (en) *	2013-02-20	2020-05-05	诺华股份有限公司	Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors
AU2014276440A1 (en) *	2013-06-03	2015-11-05	Novartis Ag	Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
MY185650A (en) *	2013-10-11	2021-05-27	Beyondspring Inc	Cancer treatment with combinantion of plinabulin and taxane

2016
- 2016-02-11 MY MYPI2017702826A patent/MY193968A/en unknown
- 2016-02-11 CN CN201680015268.XA patent/CN107427510A/en active Pending
- 2016-02-11 EP EP16749903.7A patent/EP3256130A4/en active Pending
- 2016-02-11 SG SG11201706281YA patent/SG11201706281YA/en unknown
- 2016-02-11 KR KR1020177025140A patent/KR20170117113A/en not_active Application Discontinuation
- 2016-02-11 CN CN202311274843.6A patent/CN117100753A/en active Pending
- 2016-02-11 JP JP2017560890A patent/JP7243021B2/en active Active
- 2016-02-11 IL IL286282A patent/IL286282B2/en unknown
- 2016-02-11 US US15/550,350 patent/US20180028531A1/en active Pending
- 2016-02-11 CA CA2975729A patent/CA2975729A1/en active Pending
- 2016-02-11 MX MX2017010338A patent/MX2017010338A/en unknown
- 2016-02-11 WO PCT/US2016/017602 patent/WO2016130839A1/en active Application Filing
- 2016-02-11 NZ NZ734256A patent/NZ734256A/en unknown
- 2016-02-11 RU RU2017127966A patent/RU2723021C2/en active
- 2016-02-11 AU AU2016219204A patent/AU2016219204B2/en active Active
- 2016-02-11 BR BR112017016902-9A patent/BR112017016902A2/en active IP Right Grant
2017
- 2017-08-01 IL IL253784A patent/IL253784B/en unknown
- 2017-08-10 CL CL2017002050A patent/CL2017002050A1/en unknown
- 2017-08-10 MX MX2022007472A patent/MX2022007472A/en unknown
2018
- 2018-05-31 HK HK18107194.9A patent/HK1247816A1/en unknown
2021
- 2021-01-07 JP JP2021001505A patent/JP7157181B2/en active Active
- 2021-04-21 AU AU2021202416A patent/AU2021202416B2/en active Active
2022
- 2022-11-01 JP JP2022175377A patent/JP2022190005A/en active Pending
2024
- 2024-02-02 AU AU2024200672A patent/AU2024200672A1/en active Pending

Also Published As

Publication number	Publication date
RU2017127966A3 (en)	2019-06-20
CL2017002050A1 (en)	2018-04-13
IL253784B (en)	2021-09-30
IL286282B1 (en)	2023-06-01
AU2021202416B2 (en)	2024-02-15
IL286282B2 (en)	2023-10-01
JP2021050247A (en)	2021-04-01
EP3256130A4 (en)	2018-08-01
NZ734256A (en)	2019-02-22
EP3256130A1 (en)	2017-12-20
MX2017010338A (en)	2017-12-20
JP2022190005A (en)	2022-12-22
NZ750444A (en)	2021-03-26
BR112017016902A2 (en)	2018-03-27
JP2018508572A (en)	2018-03-29
CN117100753A (en)	2023-11-24
US20180028531A1 (en)	2018-02-01
MX2022007472A (en)	2022-06-29
IL286282A (en)	2021-10-31
JP7157181B2 (en)	2022-10-19
MY193968A (en)	2022-11-03
AU2016219204A1 (en)	2017-08-24
WO2016130839A1 (en)	2016-08-18
RU2017127966A (en)	2019-03-12
CA2975729A1 (en)	2016-08-18
HK1247816A1 (en)	2018-10-05
CN107427510A (en)	2017-12-01
KR20170117113A (en)	2017-10-20
JP7243021B2 (en)	2023-03-22
IL253784A0 (en)	2017-09-28
AU2024200672A1 (en)	2024-02-22
AU2016219204B2 (en)	2021-01-21
RU2723021C2 (en)	2020-06-08
AU2021202416A1 (en)	2021-05-20

Publication	Publication Date	Title
IL286282A (en)	2021-10-31	Use of plinabulin in combination with immune checkpoint inhibitors
HK1243072A1 (en)	2018-07-06	Bromodomain inhibitors and uses thereof
HUE043847T2 (en)	2019-09-30	Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EP3233123A4 (en)	2018-05-09	Use of immune checkpoint inhibitors in central nervous systems neoplasms
IL251051A0 (en)	2017-04-30	Mk2 inhibitors and uses thereof
PL3231605T3 (en)	2021-10-18	Elastic laminate and article containing same
GB201617085D0 (en)	2016-11-23	Compare and delay instructions
HK1254954A1 (en)	2019-08-02	Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
HUE051268T2 (en)	2021-03-01	Immune checkpoint inhibitor combinations
PL3078489T3 (en)	2022-06-20	Elastic laminate and article containing same
HK1243077A1 (en)	2018-07-06	Piperidinylpyrazolopyrimidinones and their use
IL266116A (en)	2019-06-30	Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use
HK1250028A1 (en)	2018-11-23	2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
HK1250926A1 (en)	2019-01-18	Inhibitors and their uses
PT3204190T (en)	2019-02-25	Textured abrasive article and related methods
PT2944309T (en)	2019-06-05	Use of palmitoylethanolamide in combination with oppioids
GB201506127D0 (en)	2015-05-27	Immune checkpoint inhibitor combinations
GB2530075B (en)	2020-05-06	Improvements in and relating to eyewashing
PL3229772T3 (en)	2020-11-02	6-aryl-9-glycosylpurines and use thereof
GB201505971D0 (en)	2015-05-20	Inhibitors and their uses
GB201505975D0 (en)	2015-05-20	Inhibitors and their uses
GB201417432D0 (en)	2014-11-19	Improvements in and relating to pipe-breaking
GB201412345D0 (en)	2014-08-27	Improvements in and relating to devices
GB201409978D0 (en)	2014-07-16	Novel compounds and their use in therapy